Diovan competition is coming

Share this article:

Generic Diovan is coming. The Wall Street Journal reports that generics drugmaker Ranbaxy has scored an FDA approval to manufacture an off-brand version of the blood pressure medication. The drug will be manufactured at a US facility—the FDA has banned items from its facilities in India.

The approval's significance signals the end of a Novartis honeymoon: Ranbaxy held exclusive rights to deliver the first generic Diovan, and its inability to get an approval meant the branded drug sold without a competitively priced alternative even though the patent had lapsed. It also meant generics makers other than Ranbaxy were blocked from producing generic Diovan until Ranbaxy rolled out its iteration.

Bloomberg estimated in April that the lack of generic competition cost consumers around $900 million in savings.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.